Achieve Life Sciences (ACHV) CEO granted 645,000 options with long vesting

Rhea-AI Filing Summary

Achieve Life Sciences chief executive Richard Alistair Stewart received a new stock option grant covering 645,000 shares of common stock. The options have an exercise price of $4.36 per share and expire on January 28, 2036.

According to the filing, one quarter of the award will vest on the first anniversary of January 28, 2026, with the remaining options vesting in substantially equal monthly installments over the following 36 months, contingent on Stewart continuing to provide service to the company on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stewart Richard Alistair

(Last) (First) (Middle)

22722 29TH DR SE

SUITE 100

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	01/28/2026		A		645,000		(1)	01/28/2036	Common Stock	645,000	$0	645,000	D

Explanation of Responses:

1. The option will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	Sandra Thomson as attorney-in-fact for Richard Stewart	01/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the ACHV Form 4 filed for Richard Alistair Stewart report?

The Form 4 reports that Achieve Life Sciences CEO Richard Alistair Stewart received a grant of stock options for 645,000 shares of common stock, providing him the right to purchase company shares under a long-term equity incentive award, subject to vesting conditions tied to continued service.

How many stock options did the ACHV CEO receive in this Form 4 filing?

Richard Alistair Stewart received 645,000 stock options. These options give him the right to buy 645,000 shares of Achieve Life Sciences common stock, subject to a multi-year vesting schedule that begins one year after January 28, 2026 and continues in monthly installments.

What is the exercise price and expiration date of the ACHV CEO stock options?

The stock options granted to Richard Alistair Stewart carry an exercise price of $4.36 per share and expire on January 28, 2036. This means he can purchase Achieve Life Sciences shares at $4.36 any time after vesting and before that expiration date.

How do the ACHV CEO’s stock options vest according to the Form 4?

The options vest as to one quarter of the total award on the first anniversary of January 28, 2026. The remaining three quarters then vest in substantially equal monthly installments over 36 months, provided Stewart continues to serve Achieve Life Sciences on each vesting date.

What role does Richard Alistair Stewart hold at Achieve Life Sciences (ACHV)?

Richard Alistair Stewart is both a director and the Chief Executive Officer of Achieve Life Sciences. The Form 4 identifies him in these roles, indicating that the reported stock option grant is part of his equity-based executive compensation tied to the company’s performance and service.

Is the 645,000-share option grant to the ACHV CEO a direct or indirect holding?

The Form 4 shows the 645,000 stock options as a direct holding by Richard Alistair Stewart. The ownership form is reported as “D” for direct, and there is no indication in the footnotes that the options are held through a separate entity or trust.